Breast Cancer: Current Research
Open Access

Breast cancer; Genetic factors; Epigenetic factors; Oncogenes; Tumor suppressor genes; Mutations; Chromosomal rearrangements; DNA methylation; Histone modifications; Non-coding RNAs; Targeted therapy

Introduction

Breast cancer is a multifactorial disease characterized by genetic and epigenetic alterations that contribute to its initiation, progression, and response to therapy. Advances in genomic and epigenome technologies have enabled the comprehensive profiling of breast cancer genomes and epigenome, uncovering the complexity of molecular alterations driving disease pathogenesis. Understanding the interplay between genetic and epigenetic factors is essential for elucidating the molecular mechanisms underlying breast cancer and identifying novel therapeutic targets for precision medicine approaches [1].

Methodology

Genetic factors: Genetic alterations play a central role in breast cancer development and progression, with mutations in key oncogenes and tumor suppressor genes driving tumorigenesis. Mutations in the BRCA1 and BRCA2 genes, involved in DNA repair and genome stability, are well-established genetic risk factors for hereditary breast cancer. Additionally, mutations in other genes, such as TP53, PIK3CA, and PTEN, contribute to sporadic breast cancer development and are associated with aggressive tumor phenotypes and poor prognosis [2].

Copy number variations (CNVs) and chromosomal rearrangements, such as amplifications of the ERBB2 (HER2) gene and translocations involving the ESR1 gene, are also common genetic alterations observed in breast cancer. These genomic aberrations can drive oncogenic signaling pathways, confer therapeutic resistance, and influence treatment outcomes in breast cancer patients [3-5].

Epigenetic factors: Epigenetic modifications play a critical role in regulating gene expression patterns and cellular phenotypes in breast cancer. DNA methylation, histone modifications and non-coding RNAs, including microRNAs and long non-coding RNAs, constitute major epigenetic mechanisms that contribute to breast cancer pathogenesis [6].

Aberrant DNA methylation patterns, characterized by hypermethylation of tumor suppressor gene promoters and hypomethylation of oncogene promoters, are commonly observed in breast cancer and are associated with tumor initiation, progression, and metastasis. Histone modifications, such as acetylation, methylation, and phosphorylation, regulate chromatin structure and gene transcription in breast cancer cells, influencing cellular processes such as proliferation, invasion, and apoptosis [7].

Non-coding RNAs, including microRNAs and long non-coding RNAs, play diverse roles in breast cancer by modulating gene expression networks and signaling pathways. Dysregulation of microRNA expression has been linked to breast cancer development, metastasis, and therapy resistance, highlighting their potential as diagnostic and prognostic biomarkers [8].

Therapeutic implications: Genetic and epigenetic factors have significant implications for breast cancer therapy and patient management. Targeted therapies directed against specific genetic alterations, such as HER2-targeted therapies for HER2-positive breast cancer and PARP inhibitors for BRCA-mutant breast cancer, have transformed treatment paradigms and improved outcomes for subsets of breast cancer patients [9].

In addition, epigenetic therapies aimed at reversing aberrant DNA methylation or histone modifications are being investigated as potential treatment strategies for breast cancer. Drugs targeting DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and other epigenetic regulators have shown promise in preclinical and clinical studies, either as monotherapy or in combination with conventional therapies [10].

Discussion

The onset and progression of breast cancer are influenced by a myriad of genetic and epigenetic factors that regulate tumor initiation, growth, and response to therapy. Understanding the intricate interplay between these factors is crucial for unraveling the molecular mechanisms underlying breast cancer pathogenesis and identifying novel therapeutic targets for improved patient outcomes.

Challenges and opportunities: Despite significant advancements in our understanding of the genetic and epigenetic landscape of breast cancer, several challenges remain in translating this knowledge into improved patient care. Tumor heterogeneity, treatment resistance, and the complexity of genetic and epigenetic interactions pose challenges for the development of effective targeted therapies and personalized treatment strategies. However, ongoing research efforts aimed at elucidating the molecular mechanisms underlying breast cancer and identifying novel therapeutic targets offer promising opportunities for improving therapy response and patient outcomes.

Genetic and epigenetic factors play critical roles in shaping breast cancer onset and therapy response. Integrating genetic and epigenetic biomarkers into clinical practice has the potential to improve risk assessment, prognosis and treatment selection for breast cancer patients, ultimately leading to more personalized and effective therapeutic strategies. Continued research efforts aimed at unraveling the complex interplay between genetic and epigenetic factors in breast cancer will be essential for advancing our understanding of the disease and translating these findings into clinical applications for improved patient care.

Conclusion

Genetic and epigenetic factors play critical roles in shaping breast cancer onset and therapy response. Advances in genomic and epigenomic profiling technologies have led to a deeper understanding of the molecular underpinnings of breast cancer and identified novel therapeutic targets for precision medicine approaches. Integrating genetic and epigenetic biomarkers into clinical practice has the potential to improve risk assessment, prognosis, and treatment selection for breast cancer patients, ultimately leading to more personalized and effective therapeutic strategies. Continued research efforts and collaborative initiatives are needed to further elucidate the complex interplay between genetic and epigenetic factors in breast cancer and translate these findings into clinical applications for improved patient outcomes.

References

1. Li X, Ma F, Yang M, Zhang J, (2022) Nanomaterial Based Analytical Methods for Breast Cancer Biomarker Detection. Mater. Today Adv 14: 100219.

Indexed at, Crossref

2. Sung H , Ferlay J, Siegel R.L, Laversanne M, Soerjomataram I, et.al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin 71: 209-249.

Indexed at, Google Scholar, CrossRef

3. Kindts I, Laenen A, Depuydt T, Weltens C (2017) Tumour bed boost radiotherapy for women after breast conserving surgery. Cochrane Database Syst Rev 11: CD011987. 

Indexed at, Google Scholar

4. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, et al. (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390: 1048-1060. 

Indexed at, Google Scholar, Crossref

5. Chinen AB, Guan CM, Jennifer JR, Barnaby SN, Merkel TJ, et.al (2015) Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 115: 10530–10574.

Indexed at, Google Scholar, CrossRef

6. Azzouz A, Hejji L, Kim K-H, Kukkar D, Souhail B, et.al (2022) Advances in Surface Plasmon Resonance-Based Biosensor Technologies for Cancer Biomarker Detection. Biosens Bioelectron 197: 113767

Indexed at, Google Scholar, CrossRef

7. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, et al. (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318: 918-926. 

Indexed at, Google Scholar, Crossref

8. Koulis TA, Phan T, Olivotto IA (2015) Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press) 7: 363-370. 

Indexed at, Google Scholar, Crossref

9. Ulucan-Karnak F, Akgöl S (2021) A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. Nanomanufacturing 1: 14-38

Indexed at, Google Scholar, CrossRef

10. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, et al. (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395: 1613-1626.

Indexed at, Google Scholar, Crossref